NCT05266014 - This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

August 15, 2023

Study Completion Date

August 15, 2023

Conditions

Stargardt Disease

Interventions

DRUG

tinlarebant

"Phase 1b Portion: tinlarebant will be self-administered orally once daily for 2 cycles, 14 days per cycle.~Phase 2 portion: tinlarebant will be self-administered orally once daily for 24 months."

Trial Locations (3)

100

National Taiwan University Hospital, Taipei

2145

Sydney Children's Hospitals Network, Westmead

6009

Lions Eye Institute, Perth